Literature DB >> 24753128

Randomization is not associated with socio-economic and demographic factors in a multi-center clinical trial of children with sickle cell anemia.

Dionna O Roberts1, Brittany Covert1, Mark J Rodeghier2, Nagina Parmar3, Michael R DeBaun1, Alexis A Thompson4, Robert I Liem4.   

Abstract

BACKGROUND: Few studies have investigated factors influencing participation rates for minority children with a chronic disease in clinical trials. The Silent Cerebral Infarct Multi-Center Clinical (SIT) Trial provides an opportunity to study the impact of demographic and socio-economic factors on randomization in a clinical trial among Black children. Our primary objective was to characterize the factors associated with successful randomization of children with sickle cell disease (SCD) and silent cerebral infarct (SCI) in the SIT Trial after initial consent. PROCEDURE: Differences in socio-economic and demographic variables, family history and disease-related variables were determined between eligible participants who were successfully randomized and those who were not randomized following initial consent. Head of household educational level and family income were examined separately for US versus non-US sites.
RESULTS: Of 1,176 children enrolled in the SIT Trial, 1,016 (86%) completed screening. Of 208 (20%) children with qualifying SCI on pre-randomization MRI, 196 (94%) were successfully randomized. There were no differences in socio-economic, demographic, or disease-related variables between children who were or were not randomized. Participants from non-US sites were more likely to be randomized (22% vs. 12%, P = 0.011); although, randomization by country was associated with neither head of household education nor family income.
CONCLUSION: In the SIT Trial, acceptance of random allocation was not associated with socio-economic or demographic factors. Although these factors may represent barriers for some participants, they should not bias investigators caring for children with SCD in their approach to recruitment for clinical trial participation.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  clinical trials; randomization; research participation; sickle cell disease; study recruitment

Mesh:

Year:  2014        PMID: 24753128      PMCID: PMC4107131          DOI: 10.1002/pbc.25072

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  25 in total

1.  Racial variation in treatment preferences and willingness to randomize in the Spine Patient Outcomes Research Trial (SPORT).

Authors:  Addisalem Arega; Nancy J O Birkmeyer; Jon D N Lurie; Tor Tosteson; Jennifer Gibson; Brett A Taylor; Tamara Shawver Morgan; James N Weinstein
Journal:  Spine (Phila Pa 1976)       Date:  2006-09-01       Impact factor: 3.468

2.  Initial development of a questionnaire evaluating perceived benefits and barriers to pediatric clinical trials participation.

Authors:  Lamia P Barakat; Chavis A Patterson; Valerie Mondestin; Veronica Chavez; Tahirah Austin; M Renée Robinson; Yimei Li; Kim Smith-Whitley; Robyn Cohen
Journal:  Contemp Clin Trials       Date:  2012-11-10       Impact factor: 2.226

3.  African Americans and participation in clinical trials: differences in beliefs and attitudes by gender.

Authors:  R BeLue; K D Taylor-Richardson; J Lin; A T Rivera; D Grandison
Journal:  Contemp Clin Trials       Date:  2006-08-10       Impact factor: 2.226

4.  Correlates of parental participation during informed consent for randomized clinical trials in the treatment of childhood leukemia.

Authors:  Dennis Drotar; Victoria Miller; Victoria Willard; Kyle Anthony; Eric Kodish
Journal:  Ethics Behav       Date:  2004

5.  Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.

Authors:  Lynne Penberthy; Richard Brown; Maureen Wilson-Genderson; Bassam Dahman; Gordon Ginder; Laura A Siminoff
Journal:  Clin Trials       Date:  2012-10-02       Impact factor: 2.486

6.  Parent recruitment and retention in a universal prevention program for child behavior and emotional problems: barriers to research and program participation.

Authors:  Nina Heinrichs; Heike Bertram; Annett Kuschel; Kurt Hahlweg
Journal:  Prev Sci       Date:  2005-12

7.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

Review 8.  A systematic review of the factors influencing African Americans' participation in cancer clinical trials.

Authors:  Desiree Rivers; Euna M August; Ivana Sehovic; B Lee Green; Gwendolyn P Quinn
Journal:  Contemp Clin Trials       Date:  2013-04-01       Impact factor: 2.226

Review 9.  Representation of the elderly, women, and minorities in heart failure clinical trials.

Authors:  Asefeh Heiat; Cary P Gross; Harlan M Krumholz
Journal:  Arch Intern Med       Date:  2002 Aug 12-26

10.  Intellectual function evaluation of first generation immigrant children with sickle cell disease: the role of language and sociodemographic factors.

Authors:  Maria Montanaro; Raffaella Colombatti; Marisa Pugliese; Camilla Migliozzi; Fabiana Zani; Maria Elena Guerzoni; Sheila Manoli; Renzo Manara; Giorgio Meneghetti; Patrizia Rampazzo; Francesca Cavalleri; Marco Giordan; Paolo Paolucci; Giuseppe Basso; Giovanni Palazzi; Laura Sainati
Journal:  Ital J Pediatr       Date:  2013-06-04       Impact factor: 2.638

View more
  7 in total

Review 1.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

2.  Mistrust of Pediatric Sickle Cell Disease Clinical Trials Research.

Authors:  Evelyn M Stevens; Chavis A Patterson; Yimei B Li; Kim Smith-Whitley; Lamia P Barakat
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

3.  Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes.

Authors:  Lori C Jordan; Dionna O Roberts Williams; Mark J Rodeghier; Brittany V Covert Greene; Maria R Ponisio; James F Casella; Robert C McKinstry; Michael J Noetzel; Fenella J Kirkham; Emily R Meier; Beng Fuh; Melissa McNaull; Sharada Sarnaik; Suvankar Majumdar; Timothy L McCavit; Michael R DeBaun
Journal:  Am J Hematol       Date:  2018-03-30       Impact factor: 10.047

4.  Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Authors:  Lise J Estcourt; Ruchika Kohli; Sally Hopewell; Marialena Trivella; Winfred C Wang
Journal:  Cochrane Database Syst Rev       Date:  2020-07-27

5.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Catherine Kimber; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2020-04-06

Review 6.  Pediatric Stroke: Overview and Recent Updates.

Authors:  Mary Hollist; Katherine Au; Larry Morgan; Padmashri A Shetty; Riddhi Rane; Abraham Hollist; Angela Amaniampong; Batool F Kirmani
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

7.  Blood transfusions for treating acute chest syndrome in people with sickle cell disease.

Authors:  Roya Dolatkhah; Saeed Dastgiri
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.